Vaccines for post-exposure prophylaxis against varicella (chickenpox) in children and adults

Cochrane Database of Systematic Reviews

Volumn 2014, Issue 6, 2014, Pages

  Macartney, Kristine ^a   Heywood, Anita ^b   Mcintyre, Peter ^a  

^a CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CHICKENPOX VACCINE; PLACEBO; LIVE VACCINE;

ADULT; CHICKENPOX; CHILD; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; FEVER; FOLLOW UP; HUMAN; INJECTION SITE REACTION; LABORATORY TEST; OUTCOME ASSESSMENT; POST EXPOSURE PROPHYLAXIS; PRIORITY JOURNAL; QUALITY CONTROL; REVIEW; SYSTEMATIC REVIEW; VACCINATION; PROCEDURES; RANDOMIZED CONTROLLED TRIAL (TOPIC); TRANSMISSION; VARICELLA ZOSTER VIRUS;

ADULT; CHICKENPOX; CHICKENPOX VACCINE; CHILD; HERPESVIRUS 3, HUMAN; HUMANS; POST-EXPOSURE PROPHYLAXIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; VACCINES, ATTENUATED;

EID: 84942752749     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD001833.pub3     Document Type: Review

References (296)

1. Arbeter AM, Starr SE, Weibel RE, Plotkin SA. Varicella vaccine studies in healthy children and adults. Pediatrics 1986;78(Suppl):748-56.
2. Asano Y, Nakayama H, Yazaki T, Kato R, Hirose S. Protection against varicella in family contacts by immediate inoculation with live varicella vaccine. Pediatrics 1977;59:3-7.
3. Mor M, Harel L, Kahan E, Amir J. Efficacy of postexposure immunization with live attenuated varicella vaccine in the household setting - a pilot study. Vaccine 2004;23:325-8.
4. Akazawa M, Yongue J, Ikeda S, Satoh T. Considering economic analyses in the revision of the preventive vaccination law: a new direction for health policy-making in Japan?. Value in Health 2013;16(7):A364.
5. Alpay H, Yildiz N, Onar A, Temizer H, Ozcay S. Varicella vaccination in children with steroid-sensitive nephrotic syndrome. Pediatric Nephrology 2002;17:181-3.
6. Ampofo K, Saiman L, LaRussa P, Steinberg S, Annunziato P, Gershon A. Persistence of immunity to live attenuated varicella vaccine in healthy adults. Clinical Infectious Diseases 2002;34:774-9.
7. Andrei G, Snoeck R. Emerging drugs for varicella-zoster virus infections. Expert Opinion of Emerging Drugs 2011;16(3):507-35.
8. Arbeter AM, Starr SE, Weibel RE, Plotkin SA. Live attenuated varicella vaccine: immunization of healthy children with the OKA strain. Journal of Pediatrics 1982;100:886-93.
9. Arbeter AM, Starr SE, Weibel RE, Neff BJ, Plotkin SA. Live attenuated varicella vaccine: the KMcC strain in healthy children. Pediatrics 1983;71(3):307-12.
10. Arbeter AM, Starr SE, Preblud SR, Ihara T, Paciorek PM, Miller DS, et al.Varicella vaccine trials in healthy children. A summary of comparative and follow-up studies. American Journal of Diseases of Children 1984;138:434-8.
11. Arbeter AM, Starr SE, Plotkin SA. Varicella vaccine studies in healthy children and adults. Pediatrics 1986;78:748-56.
12. Arbeter AM, Granowetter L, Starr SE, Lange B, Wimmer R, Plotkin SA. Immunization of children with acute lymphoblastic leukemia with live attenuated varicella vaccine without complete suspension of chemotherapy. Pediatrics 1990;85(3):338-44.
13. Arent PM, Cunha L, Freitas PF. Vaccination status among medical students of Universidade do Sul de Santa Catarina before internship [Situação vacinal dos estudantes de medicina da Universidade do Sul de Santa Catarina no período prévio ao internato]. Revista de Ciências Médicas 2009;18(1):13-20.
14. Asano Y, Yazaki T, Miyata T, Nakayama H, Hirose S. Application of a live attenuated varicella vaccine to hospitalized children and its protective effect on spread of varicella infection. Biken Journal 1975;18:35-40.
15. Asano Y, Takahashi M. Clinical and serologic testing of a live varicella vaccine and two-year follow-up for immunity of the vaccinated children. Pediatrics 1977;60:810-4.
16. Asano Y, Nakayama H, Yazaki T, Ito S, Isomura S. Protective efficacy of vaccination in children in four episodes of natural varicella and zoster in the ward. Pediatrics 1977;59:8-12.
17. Asano Y, Hirose S, Iwayama S, Miyata T, Yazaki T, Takahashi M. Protective effect of immediate inoculation of a live varicella vaccine in household contacts in relation to the viral dose and interval between exposure and vaccination. Biken Journal 1982;25:43-5.
18. Asano Y, Albrecht P, Vujcic LK, Quinnan GV Jr, Kawakami K, Takahashi M. Five-year follow-up study of recipients of live varicella vaccine using enhanced neutralization and fluorescent antibody membrane antigen assays. Pediatrics 1983;72(3):291-4.
19. Asano Y, Nagai T, Miyata T, Yazaki T, Ito S, Yamanishi K, et al.Persistence of protective immunity after inoculation with live varicella vaccine (strain Oka). Biken Journal 1984;27:123-8.
20. Asano Y, Nagai T, Miyata T, Yazaki T, Ito S, Yamanishi K, et al.Long-term protective immunity of recipients of the OKA strain of live varicella vaccine. Pediatrics 1985;75(4):667-71.
21. Asano Y, Suga S, Yoshikawa T, Kobayashi I, Yazaki T, Shibata M, et al.Experience and reason: twenty-year follow-up of protective immunity of the Oka strain live varicella vaccine. Pediatrics 1994;94:524-6.
22. Asano Y. Clinicopathologic understanding and control of varicella-zoster virus infection. Vaccine 2008;26(50):6487-90.
23. Bai YH, Yang LQ, Guo LS, Tao H, Ai X, Li L, et al.Safety and immunogenicity of gelatin-free freeze-dried live attenuated varicella vaccine. Chinese Journal of Biologicals 2011;24(11):1336-8.
24. Baldacci ER, Fagundes SN, Koch VH. Evaluation of chickenpox susceptibility in children with chronic renal failure [Avaliação da suscetibilidade à varicela no paciente pediátrico portador de insuficiência renal crônica]. Revista Paulista de Pediatria 2008;26(1):20-6.
25. Bancillon A, Leblanc T, Baruchel A, Schaison G, Leverger G, Mallarmey D, et al.Study of tolerance and effectiveness of a varicella vaccine in leukemic children. Nouvelle Revue Francaise d'Hematologie 1991;33:555-6.
26. Banz K, Iseli A, Aebi C, Brunner M, Schmutz AM, Heininger U. Economic evaluation of varicella vaccination in Swiss children and adolescents. Human Vaccines 2009;5(12):847-57.
27. Barbosa CMP, Terreri MT, Len CA, Moraes-Pinto MI, Rosario P, Hilario MO, et al.Varicella vaccine in children and adolescents with systemic lupus erythematosus (SLE) immunogenicity and safety. Arthritis and Rheumatism 2009;60:1521.
28. Barbosa CMPL, Terreri MTRA, Rosario PO, de Moraes-Pinto MI, Silva CAA, Hilario MOE. Immune response and tolerability of varicella vaccine in children and adolescents with systemic lupus erythematosus previously exposed to varicella-zoster virus. Clinical and Experimental Rheumatology 2012;30(5):791-8.
29. Bate J, Chisholm J, Heath PT, Breuer J, Skinner R, Manley S, et al.PEPtalk: postexposure prophylaxis against varicella in children with cancer. Archives of Disease in Childhood 2011;96(9):841-5.
30. Bednarek M, Majda-Stanislawska E. Varicella vaccination safety in children with allergy. Pediatria Polska 2004;79:27-31.
31. Bekker V, Westerlaken GHA, Scherpbier H, Alders S, Zaaijer H, Van BD, et al.Varicella vaccination in HIV-1-infected children after immune reconstitution. AIDS 2006;20(18):2321-9.
32. Bergen RE, Diaz PS, Arvin AM. The immunogenicity of the Oka/Merck varicella vaccine in relation to infectious varicella-zoster virus and relative viral antigen content. Journal of Infectious Diseases 1990;162:1049-54.
33. Berger R, Luescher D, Just M. Enhancement of varicella-zoster-specific immune responses in the elderly by boosting with varicella vaccine. Journal of Infectious Diseases 1984;149(4):647.
34. Berger R, Amstutz I, Just M, Just V, Luescher D. Booster vaccination of healthy adults with VZV antibody but without a VZV-specific cell-mediated immune response. Antiviral Research 1985;Suppl 1:267-71.
35. Berger R, Trannoy E, Hollander G, Bailleux F, Rudin C, Creusvaux H. A dose-response study of a live attenuated varicella-zoster virus (Oka strain) vaccine administered to adults 55 years of age and older. Journal of Infectious Diseases 1998;178(Suppl 1):99-103.
36. Berghella V, Buchanan E, Pereira L, Baxter JK. Preconception care. Obstetrical & Gynecological Survey 2010;65(2):119-31.
37. Bernstein HH, Rothstein EP, Watson BM, Reisinger KS, Blatter MM, Wellman CO, et al.Clinical survey of natural varicella compared with breakthrough varicella after immunization with live attenuated Oka/Merck varicella vaccine. Pediatrics 1993;92:833-7.
38. Black SB, Cimino CO, Hansen J, Lewis E, Ray P, Corsaro B, et al.Immunogenicity and safety of measles-mumps-rubella, varicella and Haemophilus influenzae type b vaccines administered concurrently with a fourth dose of heptavalent pneumococcal conjugate vaccine compared with the vaccines administered without heptavalent pneumococcal conjugate vaccine. Pediatric Infectious Disease Journal 2006;25(4):306-11.
39. Black S, Ray P, Shinefield H, Saddier P, Nikas A. Lack of association between age at varicella vaccination and risk of breakthrough varicella, within the Northern California Kaiser Permanente Medical Care Program. Journal of Infectious Diseases 2008;197(Suppl 2):S139-42.
40. Blatter MM, Klein NP, Shepard JS, Leonardi M, Shapiro S, Schear M, et al.Immunogenicity and safety of two tetravalent (measles, mumps, rubella, varicella) vaccines coadministered with hepatitis A and pneumococcal conjugate vaccines to children twelve to fourteen months of age. Pediatric Infectious Disease Journal 2012;31(8):e133-40.
41. Bogger-Goren S, Baba K, Hurley P, Yabuuchi H, Takahashi M, Ogra PL. Antibody response to varicella-zoster virus after natural or vaccine-induced infection. Journal of Infectious Diseases 1982;146(2):260-5.
42. Brotons M, Campins M, Mendez L, Juste C, Rodrigo JA, Martinex X, et al.Effectiveness of varicella vaccines as postexposure prophylaxis. Pediatric Infectious Disease Journal 2010;29(1):10-3.
43. Broyer M, Boudailliez B. Varicella vaccine in children with chronic renal insufficiency. Postgraduate Medical Journal 1985;61(Suppl 4):103-6.
44. Brunell PA, Shehab Z, Geiser C, Waugh JE. Administration of live varicella vaccine to children with leukaemia. Lancet 1982;2(8307):1069-73.
45. Brunell PA, Taylor-Wiedeman J, Geiser CF, Frierson L, Lydick E. Risk of herpes zoster in children with leukemia: varicella vaccine compared with history of chickenpox. Pediatrics 1986;77(1):53-6.
46. Brunell PA, Novelli VM, Lipton SV, Pollock B. Combined vaccine against measles, mumps, rubella, and varicella. Pediatrics 1988;81:779-84.
47. Bryant K, McVernon J, Marchant C, Nolan T, Marshall G, Richmond P, et al.Immunogenicity and safety of measles-mumps-rubella and varicella vaccines coadministered with a fourth dose of Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine in toddlers: a pooled analysis of randomized trials. Human Vaccines and Immunotherapeutics 2012;8(8):1036-41.
48. Bryant KA, Gurtman A, Girgenti D, Reisinger K, Johnson A, Pride MW, et al.Antibody responses to routine pediatric vaccines administered with 13-valent pneumococcal conjugate vaccine. Pediatric Infectious Disease Journal 2013;32(4):383-8.
49. Burgess MA, Cossart YE, Wilkins TD, Botham S, Fearns G, Chitour K. Varicella vaccination of health-care workers. Vaccine 1999;17(7-8):765-9.
50. Ceyhan M, Tezer H, Yildirim I. Secondary attack rate of hepatitis A, varicella and mumps in household settings and reliability of family history to detect seronegative children for necessity of vaccination. Scandinavian Journal of Infectious Diseases 2009;41(6-7):501-6.
51. Chao DY, Chien YZ, Yeh YP, Hsu PS, Lian IB. The incidence of varicella and herpes zoster in Taiwan during a period of increasing varicella vaccine coverage, 2000-2008. Epidemiology and Infection 2012;140(6):1131-40.
52. Chlibek R, Smetana J, Pauksens K, Rombo L, Van den Hoek JAR, Richardus JH, et al.Safety and immunogenicity of three different formulations of an adjuvanted varicella-zoster virus subunit candidate vaccine in older adults: a phase II, randomized, controlled study. Vaccine 2014;32(15):1745-53.
53. Chui KS, Wu HL, You JHS. Cost-effectiveness analysis of varicella vaccine as post-exposure prophylaxis in Hong Kong. Scandinavian Journal of Infectious Diseases 2014;46(1):27-33.
54. Clements DA, Armstrong CB, Ursano AM, Moggio MM, Walter EB, Wilfert CM. Over five-year follow-up of Oka/Merck varicella vaccine recipients in 465 infants and adolescents. Pediatric Infectious Disease Journal 1995;14:874-9.
55. Contopoulos-Ioannidis DG, Seto I, Hamm MP, Thomson D, Hartling L, Ioannidis JPA, et al.Empirical evaluation of age groups and age-subgroup analyses in pediatric randomized trials and pediatric meta-analyses. Pediatrics 2012;129(Suppl 3):161-84.
56. Cristofani LM, Weinberg A, Peixoto V, Boas LS, Marques HH, Maluf Júnior PT, et al.Administration of live attenuated varicella vaccine to children with cancer before starting chemotherapy. Vaccine 1991;9(12):873-6.
57. Czajka H, Schuster V, Zepp F, Esposito S, Douha M, Willems P. A combined measles, mumps, rubella and varicella vaccine (Priorix-Tetra): immunogenicity and safety profile. Vaccine 2009;27(41):6504-11.
58. D'Angio CT, Boohene PA, Mowrer A, Audet S, Menegus MA, Schmid DS, et al.Measles-mumps-rubella and varicella vaccine responses in extremely preterm infants. Pediatrics 2007;119(3):574-9.
59. Davies J, Hallworth JA, McLeish P, Randall S, Martin BA, Buchan A, et al.Characterization and immunogenicity of a candidate subunit vaccine against varicella-zoster virus. Medical Microbiology & Immunology 1994;183(2):105-17.
60. Dennehy PH, Reisinger KS, Blatter MM, Veloudis BA. Immunogenicity of subcutaneous versus intramuscular Oka/Merck varicella vaccination in healthy children. Pediatrics 1991;88:604-7.
61. Dennehy PH, Saracen CL, Peter G. Seroconversion rates to combined measles-mumps-rubella-varicella vaccine of children with upper respiratory tract infection. Pediatrics 1994;94:514-6.
62. de Soárez PC, Novaes HMD, Sartori AMC. Impact of methodology on the results of economic evaluations of varicella vaccination programs: is it important for decision-making? [Impacto da metodologia nos resultados de avaliações econômicas de programas de vacinação da varicela: É importante para o processo de tomada de decisão?]. Cadernos Saude Publica 2009;25(Suppl 3):401-14.
63. Diaz PS, Au D, Smith S, Amylon M, Link M, Smith S, et al.Lack of transmission of the live attenuated varicella vaccine virus to immunocompromised children after immunization of their siblings. Pediatrics 1991;87(2):166-70.
64. Diaz C, Dentico P, Gonzalez R, Mendez RG, Cinquetti S, Barben JL, et al.Safety, tolerability, and immunogenicity of a two-dose regimen of high-titer varicella vaccine in subjects > or = 13 years of age. Vaccine 2006;24(47-8):6875-85.
65. Dube E, Gilca V, Sauvageau C, Bettinger JA, Boucher FD, McNeil S, et al.Clinicians' opinions on new vaccination programs implementation. Vaccine 2012;30(31):4632-7.
66. Duchateau J, Vrijens R, Nicaise J, D'Hondt E, Bogearts H, Andre FE. Stimulation of specific immune response to varicella antigens in the elderly with varicella vaccine. Postgraduate Medical Journal 1985;61(Suppl 4):147-50.
67. El-Darouti MA, Hegazy MA, Abdel Hay RA, Abdel Halim RM, Dalia M. Live attenuated varicella vaccine: a new effective adjuvant weapon in the battlefield against severe resistant psoriasis, a pilot randomized controlled trial. Journal of the American Academy of Dermatology 2012;66(3):511-3.
68. Englund JA, Suarez CS, Kelly J, Tate DY, Balfour HH Jr. Placebo-controlled trial of varicella vaccine given with or after measles-mumps-rubella vaccine. Journal of Pediatrics 1989;114:37-44.
69. Enright F, McMahon B, Washington A. Varicella outbreak in a residential home; a short report and literature review on postexposure prophylaxis. Irish Medical Journal 2006;99(5):133-5.
70. Fadrowski JJ, Furth SL. Varicella zoster virus: vaccination and implications in children with renal failure. Expert Review of Vaccines 2004;3:291-8.
71. Ferrera G, Gajdos V, Thomas S, Tran C, Fiquet A. Safety of a refrigerator-stable varicella vaccine (VARIVAX) in healthy 12- to 15-month-old children: a randomized, double-blind, cross-over study. Human Vaccines 2009;5(7):455-60.
72. Ferrera G, Cuccia M, Mereu G, Icardi G, Bona G, Esposito S, et al.Booster vaccination of pre-school children with reduced-antigen-content diphtheria-tetanus-acellular pertussis-inactivated poliovirus vaccine co-administered with measles-mumps-rubella-varicella vaccine: a randomized, controlled trial in children primed according to a 2 + 1 schedule in infancy. Human Vaccines and Immunotherapies 2012;8(3):355-62.
73. Fridman D, Monti A, Bonnet MC, Armoni J, Stamboulian D. Safety of a second dose of varicella vaccine administered at 4 to 6 years of age in healthy children in Argentina. Human Vaccines 2011;7(10):1066-71.
74. Fu C, Wang M, Liang J, Xu J, Wang C, Bialek S. The effectiveness of varicella vaccine in China. Pediatric Infectious Disease Journal 2010;29(8):690-3.
75. Furth SL, Hogg RJ, Tarver J, Moulton LH, Chan C, Fivush BA, et al.Varicella vaccination in children with chronic renal failure. A report of the Southwest Pediatric Nephrology Study Group. Pediatric Nephrology 2003;18:33-8.
76. Furth SL, Arbus GS, Hogg R, Tarver J, Chan C, Fivush BA, et al.Varicella vaccination in children with nephrotic syndrome: a report of the Southwest Pediatric Nephrology Study Group. Journal of Pediatrics 2003;142:145-8.
77. Gatchalian S, Leboulleux D, Desauziers E, Bermal N, Borja-Tabora C. Immunogenicity and safety of a varicella vaccine, Okavax, and a trivalent measles, mumps and rubella vaccine, MMR-II, administered concomitantly in healthy Filipino children aged 12-24 months. Southeast Asian Journal of Tropical Medicine & Public Health 2003;34:589-97.
78. Gatchalian S, Tabora C, Bermal N, Leboulleux D, Desauziers E. Immunogenicity and safety of a varicella vaccine (Okavax) and a trivalent measles, mumps, and rubella vaccine (Trimovax) administered concomitantly in healthy Filipino children 12-24 months old. American Journal of Tropical Medicine & Hygiene 2004;70:273-7.
79. Gershon AA, Steinberg S, Borkowsky W. Clinical trial of live attenuated varicella vaccine in high risk susceptibles--a preliminary report. Developments in Biological Standardization 1982;52:391-7.
80. Gershon AA, Steinberg SP, Gelb L, Galasso G, Borkowsky W, LaRussa P, et al.Live attenuated varicella vaccine. Efficacy for children with leukemia in remission. JAMA 1984;252(3):355-62.
81. Gershon AA, Steinberg S, Gelb L, Galasso G, Borkowsky W, LaRussa P, et al.A multicentre trial of live attenuated varicella vaccine in children with leukaemia in remission. Postgraduate Medical Journal 1985;61(Suppl 4):73-8.
82. Gershon AA, Steinberg SP, Gelb L. Live attenuated varicella vaccine use in immunocompromised children and adults. Pediatrics 1986;78(4 Pt 2):757-62.
83. Gershon AA, Steinberg SP, LaRussa P, Ferrara A, Hammerschlag M, Gelb L. Immunization of healthy adults with live attenuated varicella vaccine [Erratum appears in J Infect Dis 1988 Nov;158(5):1149]. Journal of Infectious Diseases 1988;158:132-7.
84. Gershon AA, Steinberg SP. Persistence of immunity to varicella in children with leukemia immunized with live attenuated varicella vaccine. New England Journal of Medicine 1989;320:892-7.
85. Gershon AA, Steinberg SP. Live attenuated varicella vaccine: protection in healthy adults compared with leukemic children. National Institute of Allergy and Infectious Diseases Varicella Vaccine Collaborative Study Group. Journal of Infectious Diseases 1990;161:661-6.
86. Getaz L, Siegrist C, Stoll B, Humair J, Scherrer Y, Franziskakis C, et al.Chickenpox in a Swiss prison: susceptibility, post-exposure vaccination and control measures. Scandinavian Journal of Infectious Diseases 2010;42:936-40.
87. Giacchino R, Marcellini M, Timitilli A, Degli IL, Losurdo G, Palumbo M, et al.Varicella vaccine in children requiring renal or hepatic transplantation. Transplantation 1995;60:1055-6.
88. Gilderman LI, Lawless JF. A double-blind, randomized, controlled, multicenter safety and immunogenicity study of a refrigerator-stable formulation of Zostavax. Clinical and Vaccine Immunology 2008;15(2):314-9.
89. Gillett Y, Steri GC, Behre U, Arsene JP, Lanse X, Helm K, et al.Immunogenicity and safety of measles-mumps-rubella-varicella (MMRV) vaccine followed by one dose of varicella vaccine in children aged 15 months-2 years or 2-6 years primed with measles-mumps-rubella (MMR) vaccine. Vaccine 2009;27(3):446-53.
90. Gillet Y, Habermehl P, Thomas S, Eymin C, Fiquet A. Immunogenicity and safety of concomitant administration of a measles, mumps and rubella vaccine (M-M-RvaxPro) and a varicella vaccine (VARIVAX) by intramuscular or subcutaneous routes at separate injection sites: a randomised clinical trial. BMC Medicine 2009;7:16.
91. Glanz JM, McClure DL, Magid DJ, Daley MF, France EK, Hambidge SJ. Parental refusal of varicella vaccination and the associated risk of varicella infection in children. Archives of Pediatrics and Adolescent Medicine 2010;164(1):66-70.
92. Gnann JW Jr. Vaccination to prevent herpes zoster in older adults. Journal of Pain 2008;9(1 Suppl 1):S31-6.
93. Gonzaga MA, Cruz AS, Ganem NS, Gaspar Filho MG, Simas TB. Contact with infectious diseases [Conduta nos contatos de doenças infecto-contagiosas]. Jornal Brasileiro de Medicina 2008;94(6):11-8.
94. Groves KC, Averbeck K, Quinlivan ML, Scott FT, Breuer J. A case of nosocomial VZV transmission. Journal of Clinical Virology 2010;48(3):226-7.
95. Guerra FA, Gress J, Werzberger A, Reisinger K, Walter E, Lakkis H, et al.Safety, tolerability and immunogenicity of VAQTA given concomitantly versus nonconcomitantly with other pediatric vaccines in healthy 12-month-old children. Pediatric Infectious Disease Journal 2006;25(10):912-9.
96. Ha K, Baba K, Ikeda T, Nishida M, Yabuuchi H, Takahashi M. Application of live varicella vaccine to children with acute leukemia or other malignancies without suspension of anticancer therapy. Pediatrics 1980;65(2):346-50.
97. Habermehl P, Lignitz A, Knuf M, Schmitt HJ, Slaoui M, Zepp F. Cellular immune response of a varicella vaccine following simultaneous DTaP and VZV vaccination. Vaccine 1999;17(7-8):669-74.
98. Halperin SA, Ferrera G, Scheifele D, Predy G, Stella G, Cuccia M, et al.Safety and immunogenicity of a measles-mumps-rubella-varicella vaccine given as a second dose in children up to six years of age. Vaccine 2009;27(20):2701-6.
99. Hambleton S, Steinberg SP, Larussa PS, Shapiro ED, Gershon AA. Risk of herpes zoster in adults immunized with varicella vaccine. Journal of Infectious Disease 2008;197(Suppl 2):196-9.
100. Hardy I, Gershon AA, Steinberg SP, LaRussa P. The incidence of zoster after immunization with live attenuated varicella vaccine. A study in children with leukemia. Varicella Vaccine Collaborative Study Group. New England Journal of Medicine 1991;325:1545-50.
101. Hartung HP, Bezuidenhoudt M, Sfikas N, Karan R, Von Rosenstiel P, Putzki N. Immunity to varicella zoster virus in clinical trials of fingolimod in patients with multiple sclerosis. Multiple Sclerosis 2013;19(11):494-5.
102. Hata A, Asanuma H, Rinki M, Sharp M, Wong RM, Blume K. Use of an inactivated varicella vaccine in recipients of hematopoietic-cell transplants. New England Journal of Medicine 2002;347:26-34.
103. Hayward A, Villanueba E, Cosyns M, Levin M. Varicella-zoster virus (VZV)-specific cytotoxicity after immunization of nonimmune adults with Oka strain attenuated VZV vaccine. Journal of Infectious Diseases 1992;166:260-4.
104. Hayward AR, Buda K, Levin MJ. Immune response to secondary immunization with live or inactivated VZV vaccine in elderly adults. Viral Immunology 1994;7:31-6.
105. Hayward AR, Buda K, Jones M, White CJ, Levin MJ. Varicella zoster virus-specific cytotoxicity following secondary immunization with live or killed vaccine. Viral Immunology 1996;9(4):241-5.
106. Heller L, Berglund G, Ahstrom L, Hellstrand K, Wahren B. Early results of a trial of the Oka-strain varicella vaccine in children with leukaemia or other malignancies in Sweden. Postgraduate Medical Journal 1985;61(Suppl 4):79-83.
107. Hesley TM, Reisinger KS, Sullivan BJ, Jensen EH, Stasiorowski S, Meechan C, et al.Concomitant administration of a bivalent Haemophilus influenzae type b-hepatitis B vaccine, measles-mumps-rubella vaccine and varicella vaccine: safety, tolerability and immunogenicity. Pediatric Infectious Disease Journal 2004;23:240-5.
108. Holcomb K, Weinberg JM. A novel vaccine (Zostavax) to prevent herpes zoster. Giornale Italiano di Dermatologia e Venereologia 2008;143(2):119-23.
109. Horiuchi K. Chickenpox vaccination of healthy children: immunological and clinical responses and protective effect in 1978-1982. Biken Journal 1984;27(2-3):37-8.
110. Huang LM, Lee BW, Chan PC, Povey M, Henry O. Immunogenicity and safety of combined measles-mumps-rubella-varicella vaccine using new measles and rubella working seeds in healthy children in Taiwan and Singapore: a phase II, randomized, double-blind trial. Human Vaccines and Immunotherapeutics 2013;9(6):1308-15.
111. Iovlev VI, Boichuk LM, Kuz'micheva AT, Ivanova MV, Smorodintsev AA. Reactogenic and immunogenic properties of an attenuated strain of chicken pox virus. Voprosy Neirokhirurgii 1969;33(5):561-5.
112. Izawa T, Ihara T, Hattori A, Iwasa T, Kamiya H, Sakurai M, et al.Application of a live varicella vaccine in children with acute leukemia or other malignant diseases. Pediatrics 1977;60(6):805-9.
113. Johnson CE, Shurin PA, Fattlar D, Rome LP, Kumar ML. Live attenuated varicella vaccine in healthy 12- to 24-month-old children. Pediatrics 1988;81(4):512-8.
114. Johnson C, Rome LP, Stancin T, Kumar ML. Humoral immunity and clinical reinfections following varicella vaccine in healthy children. Pediatrics 1989;84(3):418-21.
115. Jones L, Malavige G, Jeffery K, Kemp E, Breuer J, Klenerman P, et al.Tracking epitope-specific antiviral CD4+ T cell responses to a live attenuated vaccine reveals ongoing functional responses. Vaccine 2009;27(52):7398-401.
116. Just M, Berger R, Luescher D. Live varicella vaccine in healthy individuals. Postgraduate Medical Journal 1985;61(Suppl 4):129-32.
117. Just M, Berger R, Just V. Evaluation of a combined measles-mumps-rubella-chickenpox vaccine. Developments in Biological Standardization 1986;65:85-8.
118. Kanra G, Ceyhan M, Ozmert E. Safety and immunogenicity of live attenuated varicella vaccine in 9-month-old children. Pediatrics International 2000;42(6):674-7.
119. Katsushima N, Yazaki N, Sakamoto M, Fujiyama J, Nakagawa M, Okuyama Y, et al.Application of a live varicella vaccine to hospitalized children and its follow-up study. Biken Journal 1982;25(1):29-42.
120. Katsushima N, Yazaki N, Sakamoto M. Effect and follow-up study on varicella vaccine. Biken Journal 1984;27(2-3):51-8.
121. Klein NP, Shepard J, Bedell L, Odrljin T, Dull P. Immunogenicity and safety of a quadrivalent meningococcal conjugate vaccine administered concomitantly with measles, mumps, rubella, varicella vaccine in healthy toddlers. Vaccine 2012;30(26):3929-36.
122. Klein NP, Weston WM, Kuriyakose S, Kolhe D, Howe B, Friedland LR, et al.An open-label, randomized, multi-center study of the immunogenicity and safety of DTaP-IPV (Kinrix) co-administered with MMR vaccine with or without varicella vaccine in healthy pre-school age children. Vaccine 2012;30(3):668-74.
123. Knuf M, Habermehl P, Zepp F, Mannhardt W, Kuttnig M, Muttonen P, et al.Immunogenicity and safety of two doses of tetravalent measles-mumps-rubella-varicella vaccine in healthy children. Pediatric Infectious Disease Journal 2006;25(1):12-8.
124. Knuf M, Zepp F, Meyer CU, Habermehl P, Maurer L, Burow HM, et al.Safety, immunogenicity and immediate pain of intramuscular versus subcutaneous administration of a measles-mumps-rubella-varicella vaccine to children aged 11-21 months. European Journal of Pediatrics 2010;169(8):925-33.
125. Knuf M, Zepp F, Helm K, Maurer H, Prieler A, Kieninger-Baum D, et al.Antibody persistence for 3 years following two doses of tetravalent measles-mumps-rubella-varicella vaccine in healthy children. European Journal of Pediatrics 2012;171(3):463-70.
126. Konno T, Yamaguchi Y, Minegishi M, Goto Y, Tsuchiya S. A clinical trial of live attenuated varicella vaccine (Biken) in children with malignant diseases. Biken Journal 1984;27(2-3):73-5.
127. Kosuwon P, Sutra S, Kosalaraksa P. Advantage of a two-dose versus one-dose varicella vaccine in healthy non-immune teenagers and young adults. Southeast Asian Journal of Tropical Medicine & Public Health 2004;35(3):697-701.
128. Krah DL, Cho I, Schofield T, Ellis RW. Comparison of gpELISA and neutralizing antibody responses to Oka/Merck live varicella vaccine (Varivax) in children and adults. Vaccine 1997;15(1):61-4.
129. Krause PR, Klinman DM. Efficacy, immunogenicity, safety, and use of live attenuated chickenpox vaccine. Journal of Pediatrics 1995;127:518-25.
130. Kreth HW, Prager J, Raue W, Sitzmann FC, Stehr K, Stuck B, et al.Double-blind randomised study on the immunogenicity and reactogenicity of three different selections with two different virus titers each of a newly formulated attenuated varicella vaccine (Oka-phylum) [trans]. Monatsschrift fur Kinderheilkunde 1994;142(Suppl):143.
131. Kreth HW, Hoeger PH, The Members of the VZV-AD study group. Safety, reactogenicity, and immunogenicity of live attenuated varicella vaccine in children between 1 and 9 years of age with atopic dermatitis. European Journal of Pediatrics 2006;165(10):677-83.
132. Kreth HW, Lee BW, Kosuwon P, Salazar J, Gloriani-Barzaga N, Bock HL, et al.Sixteen years of global experience with the first refrigerator-stable varicella vaccine (Varilrix™). Biodrugs 2008;22(6):387-402.
133. Kumagai T, Chiba Y, Fujiwara M, Hanazono H, Nakamura S, Chiba S, et al.Humoral and cellular immune response to varicella-zoster virus in children inoculated with live attenuated varicella vaccine. Biken Journal 1980;23(3):135-41.
134. Kuter BJ, Weibel RE, Guess HA, Matthews H, Morton DH, Neff BJ, et al.Oka/Merck varicella vaccine in healthy children: final report of 2 year efficacy study and 7 year follow up studies. Vaccine 1991;9:643-7.
135. Kuter BJ, Ngai A, Patterson CM, Staehle BO, Cho I, Matthews H, et al.Safety, tolerability, and immunogenicity of two regimens of Oka/Merck varicella vaccine (Varivax) in healthy adolescents and adults. Oka/Merck Varicella Vaccine Study Group. Vaccine 1995;13:967-72.
136. Kuter B, Matthews H, Shinefield H, Black S, Dennehy P, Watson B, et al.Ten year follow-up of healthy children who received one or two injections of varicella vaccine. Pediatric Infectious Disease Journal 2004;23:132-7.
137. Kuter BJ, Brown ML, Hartzel J, Williams WR, EvesiKaren A, Black S, et al.Safety and immunogenicity of a combination measles, mumps, rubella and varicella vaccine (ProQuad). Human Vaccines 2006;2(5):205-14.
138. Lau YL, Vessey SJ, Chan IS, Lee TL, Huang LM, Lee CY, et al.A comparison of safety, tolerability and immunogenicity of Oka/Merck varicella vaccine and VARILRIX in healthy children. Vaccine 2002;20:2942-9.
139. Lawrence R, Gershon AA, Holzman R, Steinberg SP. The risk of zoster after varicella vaccination in children with leukemia. New England Journal of Medicine 1988;318:543-8.
140. Leonardi M, Bromberg K, Baxter R, Gardner JL, Klopfer S, Nicholson O, et al.Immunogenicity and safety of MMRV and PCV-7 administered concomitantly in healthy children. Pediatrics 2011;128(6):e1387-94.
141. Leroux-Roels I, Leroux-Roels G, Clement G, Vandepapeliere P, Vassilev V, Ledent E, et al.A phase 1/2 clinical trial evaluating safety and immunogenicity of a varicella zoster glycoprotein e subunit vaccine candidate in young and older adults. Journal of Infectious Disease 2012;206(8):1280-90.
142. Leung TF, Li CK, Hung EC, Chan PK, Mo CW, Wong RP, et al.Immunogenicity of a two-dose regime of varicella vaccine in children with cancers. European Journal of Haematology 2004;72:353-7.
143. Levin MJ, Murray M, Rotbart HA, Zerbe GO, White CJ, Hayward AR. Immune response of elderly individuals to a live attenuated varicella vaccine. Journal of Infectious Diseases 1992;166:253-9.
144. Levin MJ, Ellison MC, Zerbe GO, Barber D, Chan C, Stinson D, et al.Comparison of a live attenuated and an inactivated varicella vaccine to boost the varicella-specific immune response in seropositive people 55 years of age and older. Vaccine 2000;18(25):2915-20.
145. Levin MJ, Gershon AA, Weinberg A, Blanchard S, Nowak B, Palumbo P, et al.Immunization of HIV-infected children with varicella vaccine. Journal of Pediatrics 2001;139:305-10.
146. Levin MJ, Smith JG, Kaufhold RM, Barber D, Hayward AR, Chan CY, et al.Decline in varicella-zoster virus (VZV)-specific cell-mediated immunity with increasing age and boosting with a high-hose VZV vaccine. Journal of Infectious Diseases 2003;188:1336-44.
147. Levin MJ, Oxman MN, Zhang JH, Johnson GR, Stanley H, Hayward AR, et al.Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine. Journal of Infectious Diseases 2008;197(6):825-35.
148. Levin MJ. Varicella vaccination of immunocompromised children. Journal of Infectious Diseases 2008;197(Suppl 2):200-6.
149. Li YC, Gao ZG, Tao H, Zhang Y, Zhang ZL, Han YG, et al.Safety of freeze-dried live attenuated varicella vaccine. Chinese Journal of Biologicals 2012;25(12):1667-70.
150. Lieberman JM, Williams WR, Miller JM, Black S, Shinefield H, Henderson F, et al.The safety and immunogenicity of a quadrivalent measles, mumps, rubella and varicella vaccine in healthy children: a study of manufacturing consistency and persistence of antibody. Pediatric Infectious Disease Journal 2006;25(7):615-22.
151. Lim YJ, Chew FT, Tan AY, Lee BW. Risk factors for breakthrough varicella in healthy children. Archives of Disease in Childhood 1998;79:478-80.
152. Lin TY, Wang YM, Lin ST. Application of a live varicella vaccine in children with acute leukemia or nephrotic syndrome. Taiwan i Hsueh Hui Tsa Chih [Journal of the Formosan Medical Association] 1981;80:683-90.
153. Liu J, Wang M, Gan L, Liao W, Chen J. Seroepidemiology of varicella-zoster virus infection measured by the fluorescent antibody to membrane antigen test. Chung-Hua Liu Hsing Ping Hsueh Tsa Chih [Chinese Journal of Epidemiology] 2009;30(4):371-5.
154. Lopez AS, Zhang J, Brown C, Bialek S. Varicella-related hospitalizations in the United States, 2000-2006: the 1-dose varicella vaccination era. Pediatrics 2011;127(2):238-45.
155. Lou J, Tan AM, Tan CK. Experience of varicella vaccination in acute lymphoplastic leukaemia. Singapore Medical Journal 1996;37(6):607-10.
156. Loulergue P, Fonteneau L, Armengaud JB, Momcilovic S, Levy-Bruhl D, Launay O, et al.Vaccine coverage of healthcare students in hospitals of the Paris region in 2009: The Studyvax Survey. Vaccine 2013;31(26):2835-8.
157. Lu MY, Huang LM, Lee CY, Lee PI, Chiu HH, Tsai HY. Evaluation of a live attenuated varicella vaccine in 15- to 18-month-old healthy children. Chung-Hua Min Kuo Hsiao Erh Ko i Hsueh Hui Tsa Chih 1998;39:38-42.
158. Ma R, Sun MP, Sun M, Hou WJ, Jiang GY, Peng XH, et al.Effectiveness on post-exposure vaccination of varicella and its influencing factors in elementary schools in Beijing. Zhonghua Liu Xing Bing Xue Za Zhi 2009;30(6):559-63.
159. Ma F, Luo L, Zhang L. Study on epidemiological effect of the freeze-dried attenuated live varicella vaccine. Zhongguo Jihua Mianyi 2009;15(3):193-5.
160. Macaladad N, Marcano T, Guzman M, Moya J, Jurado F, Thompson M, et al.Safety and immunogenicity of a zoster vaccine in varicella-zoster virus seronegative and low-seropositive healthy adults. Vaccine 2007;25(11):2139-44.
161. Macartney K, McLntyre P. Vaccines for post-exposure prophylaxis against varicella (chickenpox) in children and adults. Sao Paulo Medical Journal 2012;130(2):133.
162. Marin M, Meissner HC, Seward JF. Varicella prevention in the United States: a review of successes and challenges. Pediatrics 2008;122(3):e744-51.
163. Marquez-Pelaez S, Ruiz-Aragon J. A systematic review of the economic studies on vaccine against herpes zoster and postherpetic neuralgia in adults. Vacunas 2009;10(4):118-24.
164. Marshall H, Ryan P, Roberton D, Beilby J. Varicella immunisation practice: implications for provision of a recommended, non-funded vaccine. Journal of Paediatrics and Child Health 2009;45(5):297-303.
165. McAdam L, Eberhardson M, Grainger W, Papp K, Hall S, Sterling T, et al.Safety and immunogenicity of inactivated varicella-zoster virus vaccine in adults with autoimmune disease. Arthritis and Rheumatism 2013;65(12):3327.
166. Meurice F, De Bouver JL, Vandevoorde D, Woods S, Bogaerts H. Immunogenicity and safety of a live attenuated varicella vaccine (Oka/SB Bio) in healthy children. Journal of Infectious Diseases 1996;174(Suppl 3):324-9.
167. Mick G. Vaccination: a new option to reduce the burden of herpes zoster. Expert Review of Vaccines 2010;9(Suppl 3):31-5.
168. Mills R, Tyring SK, Levin MJ, Parrino J, Li X, Coll KE, et al.Safety, tolerability, and immunogenicity of zoster vaccine in subjects with a history of herpes zoster. Vaccine 2010;28(25):4204-9.
169. Morales-Castillo ME, Alvarez-Munoz MT, Solorzano-Santos F, Gonzalez-Robledo R, Jasso-Gutierrez L, Munoz-Hernandez O. Live varicella vaccine in both immunocompromised and healthy children. Archives of Medical Research 2000;31:85-7.
170. Mustafa MB, Arduino PG, Porter SR. Varicella zoster virus: review of its management. Journal of Oral Pathology and Medicine 2009;38(9):673-88.
171. Nader S, Bergen R, Sharp M, Arvin AM. Age-related differences in cell-mediated immunity to varicella-zoster virus among children and adults immunized with live attenuated varicella vaccine. Journal of Infectious Diseases 1995;171:13-7.
172. Naganuma Y, Osawa S, Takahashi R. Clinical application of a live varicella vaccine (Oka strain) in a hospital. Biken Journal 1984;27:59-61.
173. Ndumbe PM, Cradock-Watson JE, Macqueen S, Dunn H, Holzel H, Andre F, et al.Immunisation of nurses with a live varicella vaccine. Lancet 1985;1(8438):1144-7.
174. Neff BJ, Weibel RE, Villarejos VM, Buynak EB, McLean AA, Morton DH, et al.Clinical and laboratory studies of KMcC strain live attenuated varicella virus. Proceedings of the Society for Experimental Biology & Medicine 1981;166(3):339-47.
175. Ngai AL, Staehle BO, Kuter BJ, Cyanovich NM, Cho I, Matthews H, et al.Safety and immunogenicity of one vs. two injections of Oka/Merck varicella vaccine in healthy children. Pediatric Infectious Disease Journal 1996;15:49-54.
176. Nithichaiyo C, Chongsrisawat V, Hutagalung Y, Bock HL, Poovorawa Y. Immunogenicity and adverse effects of live attenuated varicella vaccine (Oka-strain) in children with chronic liver disease. Asian Pacific Journal of Allergy & Immunology 2001;19(2):101-5.
177. Nolan T, McIntyre P, Roberton D, Descamps D. Reactogenicity and immunogenicity of a live attenuated tetravalent measles-mumps-rubella-varicella (MMRV) vaccine. Vaccine 2002;21:281-9.
178. Nolan T, Bernstein DI, Block SL, Hilty M, Keyserling HL, Marchant C, et al.Safety and immunogenicity of concurrent administration of live attenuated influenza vaccine with measles-mumps-rubella and varicella vaccines to infants 12 to 15 months of age. Pediatrics 121;3:508-16.
179. Novadzki IM, Rosario Filho N. Anaphylaxis associated with the vaccine against measles, mumps and rubella [Anafilaxia associada à vacina contra sarampo, caxumba e rubéola]. Revisita de Saúde Pública 2009;44(2):372-6.
180. Oxman MN, Levin MJ, Johnson GR, Schmader KE, Straus SE, Gelb LD, et al.A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. New England Journal of Medicine 2005;352(22):2271-84.
181. Oxman MN, Levin MJ and the Shingles Prevention Study Group. Vaccination against herpes zoster and postherpetic neuralgia. Journal of Infectious Diseases 2008;197(Suppl 2):228-36.
182. Oxman MN. Herpes zoster pathogenesis and cell-mediated immunity and immunosenescence. Journal of the American Osteopathic Association 2009;109(6 Suppl 2):13-7.
183. Oxman MN. Zoster vaccine: current status and future prospects. Clinical Infectious Diseases 2010;51(2):197-213.
184. Ozaki T, Nagayoshi S, Morishima T, Isomura S, Suzuki S, Asano Y, et al.Use of a live varicella vaccine for acute leukemic children shortly after exposure in a children's ward. Biken Journal 1978;21(2):69-72.
185. Ozaki T, Matsui T, Ichikawa T, Asano Y, Yamanishi K, Takahashi M. Clinical trial of the Oka strain of live attenuated varicella vaccine on healthy children. Biken Journal 1984;27:39-42.
186. Parment PA, Svahn A, Ruden U, Brakenhielm G, Storsaeter J, Akesson L, et al.Immunogenicity and reactogenicity of a single dose of live attenuated varicella vaccine and a booster dose of measles-mumps-rubella vaccine given concomitantly at 12 years of age. Scandinavian Journal of Infectious Diseases 2003;35(10):736-42.
187. Pileggi GS, de Souza CBS, Ferriani VPL. Safety and immunogenicity of varicella vaccine in patients with juvenile rheumatic diseases receiving methotrexate and corticosteroids. Arthritis Care and Research 2010;62(7):1034-9.
188. Pinochet C, Cerda J, Hirsch T, Mieres J, Inostroza C, Abarca K. Effectiveness of varicella vaccine as post exposure prophylaxis in Chilean children [Efectividad de la vacuna antivaricela como proflaxis post exposición en niños chilenos]. Revista Chilena de Infectología 2012;29(6):635-40.
189. Prelog M, Zimmerhackl LB. Varicella vaccination in pediatric kidney and liver transplantation. Pediatric Transplantation 2010;14(1):41-7.
190. Prymula R, Bergsaker MR, Esposito S, Gothefors L, Man S, Snegova N, et al.Protection against varicella with two doses of combined measles-mumps-rubella-varicella vaccine versus one dose of monovalent varicella vaccine: a multicentre, observer-blind, randomised, controlled trial. Lancet 2014;12:61461-5. [DOI: 10.1016/S0140-6736]
191. Quian RJ, Protasio PA, Dall'Orso VP, Mas GM, Romero OC, Ferreira JN, et al.Varicella outbreak in a village in Uruguay [Estudio de un brote de varicela en un pueblo del Uruguay]. Revisita Chilena de Infectologia 2010;27(1):47-51.
192. Quien RM, Kaiser BA, Deforest A, Polinsky MS, Fisher M, Baluarte HJ. Response to the varicella vaccine in children with nephrotic syndrome. Journal of Pediatrics 1997;131:688-90.
193. Ramkissoon A, Coovadia HM, Jugnundan P, Haffejee IE, Meurice F, Vandevoorde D. Immunogenicity and safety of a live attenuated varicella vaccine in healthy Indian children aged 9-24 months. South African Medical Journal 1995;85:1295-8.
194. Redman RL, Nader S, Zerboni L, Liu C, Wong RM, Brown BW, et al.Early reconstitution of immunity and decreased severity of herpes zoster in bone marrow transplant recipients immunized with inactivated varicella vaccine. Journal of Infectious Diseases 1997;176:578-85.
195. Reisinger KS, Brown ML, Xu J, Sullivan BJ, Marshall GS, Nauert B, et al.A combination measles, mumps, rubella, and varicella vaccine (ProQuad) given to 4- to 6-year-old healthy children vaccinated previously with M-M-RII and Varivax [Erratum appears in Pediatrics. 2006 Jun;117(6):2338]. Pediatrics 2006;117(2):265-72.
196. Reuman PD, Sawyer MH, Kuter BJ, Matthews H. Safety and immunogenicity of concurrent administration of measles-mumps-rubella-varicella vaccine and PedvaxHIB vaccines in healthy children twelve to eighteen months old. The MMRV Study Group. Pediatric Infectious Disease Journal 1997;16:662-7.
197. Riera R, Sato HK. Vaccines against varicella in children and adults for post-exposure prophylaxis [Vacinas contra a varicela em crianças e adultos para profilaxia pós-exposição]. Revista Diagnóstico e Tratamento 2012;17(2):88-9.
198. Rinderknecht S, Michaels MG, Blatter M, Gaglani M, Andrews W, Abughali N, et al.Immunogenicity and safety of an inactivated hepatitis A vaccine when coadministered with measles-mumps-rubella and varicella vaccines in children less than 2 years of age. Pediatric Infectious Disease Journal 2011;30(10):e179-85.
199. Rios FFA, Mallozi MC, Solé D. Sepsis by S. aureus in a patient with atopic dermatitis and herpeticum eczema: a case report [Sepse por S. aureus em paciente com dermatite atópica e eczema herpético: relato de caso]. Revista Brasileira de Alergia e Imunopatologia 2009;32(1):35-8.
200. Ross RT, Nicolle LE, Cheang M. The varicella zoster virus: a pilot trial of a potential therapeutic agent in multiple sclerosis. Journal of Clinical Epidemiology 1997;50:63-8.
201. Rothstein EP, Bernstein HH, Ngai AL, Cho I, White CJ. Dose titration study of live attenuated varicella vaccine in healthy children. Pennridge Pediatric Associates. Journal of Infectious Diseases 1997;175:444-7.
202. Rozenbaum MH, Van Hoek AJ, Vegter S, Postma MJ. Cost-effectiveness of varicella vaccination programs: an update of the literature. Expert Review of Vaccines 2008;7(6):753-82.
203. Ruger G, Gabutti G, Rumke H, Rombo L, Bernaola E, Diez-Domingo J, et al.Safety of a 2-dose regimen of a combined measles, mumps, rubella and varicella live vaccine manufactured with recombinant human albumin. Pediatric Infectious Disease Journal 2012;31(11):1166-72.
204. Rumke HC, Loch HP, Hoppenbrouwers K, Vandermeulen C, Malfroot A, Helm K, et al.Immunogenicity and safety of a measles-mumps-rubella-varicella vaccine following a 4-week or a 12-month interval between two doses. Vaccine 2011;29(22):3842-9.
205. Sadaoka K, Okamoto S, Gomi Y, Tanimoto T, Ishikawa T, Yoshikawa T, et al.Measurement of varicella-zoster virus (VZV)-specific cell-mediated immunity: comparison between VZV skin test and interferon-(gamma) enzyme-linked immunospot assay. Journal of Infectious Diseases 2008;198(9):1327-33.
206. Saiman L, LaRussa P, Steinberg SP, Zhou J, Baron K, Whittier S, et al.Persistence of immunity to varicella-zoster virus after vaccination of healthcare workers. Infection Control & Hospital Epidemiology 2001;22:279-83.
207. Salleras L. Chapter 7. Chickenpox vaccine for adolescents and adults [Capítulo 7. Vacunación antivaricela para adolescentes y adultos]. Medicina Preventiva 2009;15(4):5-13.
208. Salleras Sanmarti L, Redonnet MS, Prat A, Garrido P, Dominguez A. Vaccines against varicella-zoster virus. Enfermedades Infecciosas y Microbiologia Clinica 2008;26(Suppl 1):29-47.
209. Salzman MB, Garcia C. Postexposure varicella vaccination in siblings of children with active varicella. Pediatric Infectious Disease Journal 1998;17:256-7.
210. Sanford M, Keating GM. Zoster vaccine (Zostavax): a review of its use in preventing herpes zoster and postherpetic neuralgia in older adults. Drugs and Aging 2010;27(2):159-76.
211. Schmid DS, Jumaan AO. Impact of varicella vaccine on varicella-zoster virus dynamics. Clinical Microbiology Reviews 2010;23(1):202-17.
212. Schuster V, Otto W, Maurer L, Tcherepnine P, Pfletschinger U, Kindler K, et al.Immunogenicity and safety assessments after one and two doses of a refrigerator-stable tetravalent measles-mumps-rubella-varicella vaccine in healthy children during the second year of life. Pediatric Infectious Disease Journal 2008;27(8):724-30.
213. Seward JF, Marin M, Vázquez M. Varicella vaccine effectiveness in the US vaccination program: a review. Journal of Infectious Diseases 2008;197(Suppl 2):82-9.
214. Shapiro ED, Vazquez M, Esposito D, Holabird N, Steinberg SP, Dziura J, et al.Effectiveness of 2 doses of varicella vaccine in children. Journal of Infectious Disease 2011;203(3):312-5.
215. Sharp M, Terada K, Wilson A, Nader S, Kinchington PE, Ruyechan WT, et al.Kinetics and viral protein specificity of the cytotoxic T lymphocyte response in healthy adults immunized with live attenuated varicella vaccine. Journal of Infectious Diseases 1992;165:852-8.
216. Shinefield HR, Black SB, Staehle BO, Adelman T, Ensor K, Ngai A, et al.Safety, tolerability and immunogenicity of concomitant injections in separate locations of M-M-R II, VARIVAX and TETRAMUNE in healthy children vs. concomitant injections of M-M-R II and TETRAMUNE followed six weeks later by VARIVAX. Pediatric Infectious Disease Journal 1998;17(11):980-5.
217. Shinefield HR, Black SB, Staehle BO, Matthews H, Adelman T, Ensor K, et al.Vaccination with measles, mumps and rubella vaccine and varicella vaccine: safety, tolerability, immunogenicity, persistence of antibody and duration of protection against varicella in healthy children. Pediatric Infectious Disease Journal 2002;21:555-61.
218. Shinefield H, Black S, Digilio L, Reisinger K, Blatter M, Gress JO, et al.Evaluation of a quadrivalent measles, mumps, rubella and varicella vaccine in healthy children. Pediatric Infectious Disease Journal 2005;24(8):665-9.
219. Shinefield H, Black S, Williams WR, Marchant C, Reisinger K, Stewart T, et al.Dose-response study of a quadrivalent measles, mumps, rubella and varicella vaccine in healthy children [Erratum appears in Pediatr Infect Dis J. 2005 Nov;24(11):983]. Pediatric Infectious Disease Journal 2005;24(8):670-5.
220. Shinefield H, Black S, Thear M, Coury D, Reisinger K, Rothstein E, et al.Safety and immunogenicity of a measles, mumps, rubella and varicella vaccine given with combined Haemophilus influenzae type b conjugate/hepatitis B vaccines and combined diphtheria-tetanus-acellular pertussis vaccines. Pediatric Infectious Disease Journal 2006;25(4):287-92.
221. Shinefield HR, Black S, Kuter BJ. Varicella immunogenicity with 1- and 2-dose regimens of measles-mumps-rubella-varicella vaccine. Journal of Infectious Diseases 2008;197(Suppl 2):152-5.
222. Simberkoff MS, Arbeit RD, Johnson GR, Oxman MN, Boardman KD, Williams HM, et al.Safety of herpes zoster vaccine in the shingles prevention study: a randomized trial. Annals of Internal Medicine 2010;152(9):545-54.
223. Smith JG, Levin M, Vessey R, Chan IS, Hayward AR, Liu X, et al.Measurement of cell-mediated immunity with a varicella-zoster virus-specific interferon-gamma ELISPOT assay: responses in an elderly population receiving a booster immunization. Journal of Medical Virology 2003;70(Suppl 1):38-41.
224. Sperber SJ, Smith BV, Hayden FG. Serologic response and reactogenicity to booster immunization of healthy seropositive adults with live or inactivated varicella vaccine. Antiviral Research 1992;17:213-22.
225. Stadtmauer EA, Sullivan K, Marty F, Dadwal SS, Papanicoleau GA, Shea TC, et al.One-year safety and immunogenicity of two formulations of an adjuvanted varicella-zoster virus (VZV) subunit candidate vaccine in adult autologous hematopoietic cell transplant (HCT) recipients. Biology of Blood and Marrow Transplantation 2013;19(2):S168-9.
226. Streng A, Seeger K, Grote V, Liese JG. Varicella vaccination coverage in Bavaria (Germany) after general vaccine recommendation in 2004. Vaccine 2010;28(35):5738-45.
227. Stuck B, Stehr K, Bock HL. Concomitant administration of varicella vaccine with combined measles, mumps, and rubella vaccine in healthy children aged 12 to 24 months of age. Asian Pacific Journal of Allergy & Immunology 2002;20:113-20.
228. Sutradhar SC, Wang WB, Schlienger K, Stek JE, Xu J, Chan ISF, et al.Comparison of the levels of immunogenicity and safety of Zostavax in adults 50 to 59 years old and in adults 60 years old or older. Clinical and Vaccine Immunology 2009;16(5):646-52.
229. Takahashi M, Otsuka T, Okuno Y, Asano Y, Yazaki T. Live vaccine used to prevent the spread of varicella in children in hospital. Lancet 1974;2(7892):1288-90.
230. Takahashi M, Kamiya H, Baba K, Asano Y, Ozaki T, Horiuchi K. Clinical experience with Oka live varicella vaccine in Japan. Postgraduate Medical Journal 1985;61(Suppl 4):61-7.
231. Takahashi M. 25 years' experience with the Biken Oka strain varicella vaccine: a clinical overview. Paediatric Drugs 2001;3:285-92.
232. Takahashi M, Okada S, Miyagawa H, Amo K, Yoshikawa K, Asada H, et al.Enhancement of immunity against VZV by giving live varicella vaccine to the elderly assessed by VZV skin test and IAHA, gpELISA antibody assay. Vaccine 2003;21:3845-53.
233. Takahashi M, Asano Y, Kamiya H, Baba K, Ozaki T, Otsuka T, et al.Development of varicella vaccine. Journal of Infectious Diseases 2008;197(Suppl 2):41-4.
234. Takayama N, Kidokoro M, Suzuki K, Morita M. Immunization of healthy children with measles-mumps-rubella trivalent vaccine simultaneously given with varicella vaccine. Kansenshogaku Zasshi [Journal of the Japanese Association for Infectious Diseases] 1992;66(6):776-80.
235. Tan AY, Connett CJ, Connett GJ, Quek SC, Yap HK, Meurice F, et al.Use of a reformulated Oka strain varicella vaccine (SmithKline Beecham Biologicals/Oka) in healthy children. European Journal of Pediatrics 1996;155:706-11.
236. Tang Y, Su JL, Xia YH, Feng SZ, Huang YD, Lin WB, et al.Safety and immunogenicity of domestic gelatin-free freeze-dried live attenuated varicella vaccine. Chinese Journal of Biologicals 2012;25(11):1516-9.
237. Terada K, Niizuma T, Ogita S, Kataoka N. Responses of varicella zoster virus (VZV)-specific immunity in seropositive adults after inhalation of inactivated or live attenuated varicella vaccine. Vaccine 2002;20(31-2):3638-43.
238. Tillieux SL, Halsey WS, Thomas ES, Voycik JJ, Sathe GM, Vassilev V. Complete DNA sequences of two Oka strain varicella-zoster virus genomes. Journal of Virology 2008;82(22):11023-44.
239. Trannoy E, Berger R, Hollander G, Bailleux F, Heimendinger P, Vuillier D, et al.Vaccination of immunocompetent elderly subjects with a live attenuate Oka strain of varicella zoster virus: a randomized, controlled, dose-response trial. Vaccine 2000;18:1700-6.
240. Ueda K, Yamada I, Goto M, Nanri T, Fukuda H, Katsuta M, et al.Use of a live varicella vaccine to prevent the spread of varicella in handicapped or immunosuppressed children including MCLS (muco-cutaneous lymphnode syndrome) patients in hospitals. Biken Journal 1977;20(3-4):117-23.
241. Varis T, Vesikari T. Efficacy of high-titer live attenuated varicella vaccine in healthy young children. Journal of Infectious Diseases 1996;174(Suppl 3):330-4.
242. Vazquez M, LaRussa PS, Gershon AA, Niccolai LM, Muehlenbein CE, Steinberg SP, et al.Effectiveness over time of varicella vaccine. JAMA 2004;291(7):851-5.
243. Vesikari T, Ohrling A, Baer M, Delem A, Bogaerts H, Andre FE. Evaluation of live attenuated varicella vaccine (Oka-RIT strain) and combined varicella and MMR vaccination in 13-17-month-old children. Acta Paediatrica Scandinavica 1991;80:1051-7.
244. Vesikari T, Baer M, Willems P. Immunogenicity and safety of a second dose of measles-mumps-rubella- varicella vaccine in healthy children aged 5 to 6 years. Pediatric Infectious Disease Journal 2007;26(2):153-8.
245. Vesikari T, Karvonen A, Lindblad N, Korhonen T, Lommel P, Willems P, et al.Safety and immunogenicity of a booster dose of the 10-valent pneumococcal nontypeable haemophilus influenzae protein D conjugate vaccine coadministered with measles-mumps-rubella-varicella vaccine in children aged 12 to 16 months. Pediatric Infectious Disease Journal 2010;29(6):e47-56.
246. Vesikari T, Becker T, Gajdos V, Fiquet A, Thomas S, Richard P, et al.Immunogenicity and safety of a two-dose regimen of a combined measles, mumps, rubella and varicella live vaccine (ProQuad(®)) in infants from 9 months of age. Vaccine 2012;30(20):3082-9.
247. Vessey SJ, Chan CY, Kuter BJ, Kaplan KM, Waters M, Kutzler DP, et al.Childhood vaccination against varicella: persistence of antibody, duration of protection, and vaccine efficacy. Journal of Pediatrics 2001;139:297-304.
248. Wang Z, Yang H, Li K, Zhang A, Feng Z, Seward JF, et al.Single-dose varicella vaccine effectiveness in school settings in China. Vaccine 2013;31(37):3834-8.
249. Watson B, Piercy S, Soppas D, Browngoehl K, Warner M, Isganitis K, et al.The effect of decreasing amounts of live virus, while antigen content remains constant, on immunogenicity of Oka/Merck varicella vaccine. Journal of Infectious Diseases 1993;168:1356-60.
250. Watson BM, Piercy SA, Plotkin SA, Starr SE. Modified chickenpox in children immunized with the Oka/Merck varicella vaccine. Pediatrics 1993;91:17-22.
251. Watson B, Gupta R, Randall T, Starr S. Persistence of cell-mediated and humoral immune responses in healthy children immunized with live attenuated varicella vaccine. Journal of Infectious Diseases 1994;169(1):197-9.
252. Watson B, Boardman C, Laufer D, Piercy S, Tustin N, Olaleye D, et al.Humoral and cell-mediated immune responses in healthy children after one or two doses of varicella vaccine. Clinical Infectious Diseases 1995;20:316-9.
253. Watson BM, Laufer DS, Kuter BJ, Staehle B, White CJ, Starr SE. Safety and immunogenicity of a combined live attenuated measles, mumps, rubella, and varicella vaccine (MMR(II)V) in healthy children [Erratum appears in J Infect Dis 1996 Jun;173(6):1529]. Journal of Infectious Diseases 1996;173(3):731-4.
254. Watson B, Seward J, Yang A, Witte P, Lutz J, Chan C, et al.Postexposure effectiveness of varicella vaccine. Pediatrics 2000;105:84-8.
255. Watson B. Humoral and cell-mediated immune responses in children and adults after 1 and 2 doses of varicella vaccine. Journal of Infectious Diseases 2008;197(Suppl 2):143-6.
256. Webb NJ, Fitzpatrick MM, Hughes DA, Brocklebank TJ, Judd BA, Lewis MA, et al.Immunisation against varicella in end stage and pre-end stage renal failure. Trans-Pennine Paediatric Nephrology Study Group. Archives of Disease in Childhood 2000;82:141-3.
257. Weibel RE, Neff BJ, Kuter BJ, Guess HA, Rothenberger CA, Fitzgerald AJ, et al.Live attenuated varicella virus vaccine. Efficacy trial in healthy children. New England Journal of Medicine 1984;310:1409-15.
258. Weibel RE, Kuter BJ, Neff BJ, Rothenberger CA, Fitzgerald AJ, Connor KA, et al.Live Oka/Merck varicella vaccine in healthy children. Further clinical and laboratory assessment. JAMA 1985;254:2435-9.
259. Weinberg A, Zhang JH, Oxman MN, Johnson GR, Hayward AR, Caulfield MJ, et al.Varicella-zoster virus-specific immune responses to herpes zoster in elderly participants in a trial of a clinically effective zoster vaccine. Journal of Infectious Diseases 2009;200(7):1068-77.
260. Weinberg A, Levin MJ, Macgregor RR. Safety and immunogenicity of a live attenuated varicella vaccine in VZV-seropositive HIV-infected adults. Human Vaccines 2010;6(4):318-21.
261. White CJ, Kuter BJ, Hildebrand CS, Isganitis KL, Matthews H, Miller WJ, et al.Varicella vaccine (VARIVAX) in healthy children and adolescents: results from clinical trials, 1987 to 1989. Pediatrics 1991;87:604-10.
262. White CJ, Kuter BJ, Ngai A, Hildebrand CS, Isganitis KL, Patterson CM, et al.Modified cases of chickenpox after varicella vaccination: correlation of protection with antibody response. Pediatric Infectious Disease Journal 1992;11:19-23.
263. White CJ. Varicella-zoster virus vaccine. Clinical Infectious Diseases 1997;24:753-61.
264. Wise RP, Salive ME, Braun MM, Mootrey GT, Seward JF, Rider LG, et al.Postlicensure safety surveillance for varicella vaccine [Erratum appears in JAMA 2000 Dec 27;284(24):3129]. JAMA 2000;284:1271-9.
265. Wu YM, Li G, Zhao WL. Immunogenicity and safety of measles-mumps-rubella-varicella vaccine: a systematic review. Chinese Journal of Evidence-Based Medicine 2010;10(7):862-8.
266. Yamaguti HY, dos Santos ACJ, de Lima GZ. Knowledge about varicella by first year healthcare students in State University of Londrina and verification of the presence of varicella scars in the students [Conhecimentos sobre varicela de alunos ingressantes em cursos da área de saúde na Universidade Estadual de Londrina e verificação da presença de cicatrizes da doença]. Semina: Ciências Biológicas e da Saúde, Londrina 2008;29(1):3-8.
267. Yerkovich ST, Rowe J, Richmond P, Suriyaarachchi D, Heaton T, Hollams E, et al.Assessment of the potency and potential immunomodulatory effects of the measles mumps rubella and varicella vaccine in infants. Vaccine 2007;25(10):1764-70.
268. Yetman RJ, Shepard JS, Duke A, Stek JE, Petrecz M, Klopfer SO, et al.Concomitant administration of hepatitis A vaccine with measles/mumps/rubella/varicella and pneumococcal vaccines in healthy 12- to 23-month-old children. Human Vaccines and Immunotherapeutics 2013;9(8):1691-7.
269. Yeung CY, Liang DC. Varicella vaccine in children with acute lymphoblastic leukemia and non-Hodgkin lymphoma. Pediatric Hematology & Oncology 1992;9:29-34.
270. Zerboni L, Nader S, Aoki K, Arvin AM. Analysis of the persistence of humoral and cellular immunity in children and adults immunized with varicella vaccine. Journal of Infectious Diseases 1998;177:1701-4.
271. Australian Technical Advisory Group on Immunisation (ATAGI). The Australian Immunisation Handbook. 10th Edition. Australian Government, 2013.
272. Black S, Shinefield H, Ray P, Lewis E, Hansen J, Schwalbe J, et al.Postmarketing evaluation of the safety and effectiveness of varicella vaccine. Pediatric Infectious Disease Journal 1999;18(12):1041-6.
273. Breuer J. Vaccination to prevent varicella and shingles. Journal of Clinical Pathology 2001;54(10):743-7.
274. Enders G, Miller E, Cradock-Watson J, Bolley I, Ridehalgh M. Consequences of varicella and herpes zoster in pregnancy: prospective study of 1739 cases. Lancet 1994;343(8912):1548-51.
275. Ferson MJ. Varicella vaccine in post-exposure prophylaxis. Communicable Diseases Intelligence 2001;25:13-5.
276. Gershon AA, Takahashi M, Seward J. Varicella vaccine. In: Plotkin SA, Orenstein WA, Offit PA editor(s). Vaccines. 6th Edition. London, UK: Saunders, 2013:837-869.
277. Gnann JW Jr, Whitley RJ. Clinical practice. Herpes zoster. New England Journal of Medicine 2002;347(5):340-6.
278. Guess HA, Broughton DD, Melton LJ III, Kurland LT. Population-based studies of varicella complications. Pediatrics 1986;78(4 Pt 2):723-7.
279. Hambleton S, Gershon AA. Preventing varicella-zoster disease. Clinical Microbiology Reviews 2005;18(1):70-80.
280. Higgins JPT, Altman DG (editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions. Chichester, UK: Wiley-Blackwell, 2011.
281. Kesson AM, Grimwood K, Burgess MA, Ferson MJ, Gilbert GL, Hogg G, et al.Acyclovir for the prevention and treatment of varicella zoster in children, adolescents and pregnancy. Journal of Paediatrics and Child Health 1996;32(3):211-7.
282. Lefebvre C, Manheimer E, Glanville J. Chapter 6: Searching for studies. In: Higgins JPT, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions. Chichester, UK: Wiley-Blackwell, 2011.
283. Macartney KK, Beutels P, McIntyre P, Burgess MA. Varicella vaccination in Australia. Journal of Paediatrics and Child Health 2005;41(11):544-52.
284. Marin M, Guris D, Chaves SS, Schmid S, Seward JF, Advisory Committee on Immunization Practices CfDCaPC. Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP). Morbidity and Mortality Weekly Report 2007;56(RR-4):1-40.
285. MMWR. Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP). Morbidity and Mortality Weekly Report 1996;45(RR-11):1-36.
286. National Advisory Committee on Immunization (NACI). National Advisory Committee on Immunization (NACI) update on varicella. Canada Communicable Disease Report 2004;30:1-26.
287. Ogilvie MM. Antiviral prophylaxis and treatment in chickenpox. A review prepared for the UK Advisory Group on Chickenpox on behalf of the British Society for the Study of Infection. Journal of Infection 1998;36(Suppl 1):31-8.
288. Pastuszac AL, Levy M, Schick B, Zuber C, Feldkamp M, Gladstone J, et al.Outcome after maternal varicella infection in the first 20 weeks of pregnancy. New England Journal of Medicine 1994;330(13):901-5.
289. Preblud SR, Orenstein WA, Bart KJ. Varicella: clinical manifestations, epidemiology and health impact in children. Pediatric Infectious Disease Journal 1984;3(6):505-9.
290. Quian J, Ruttimann R, Romero C, Dall'Orso P, Cerisola A, Breuer T, et al.Impact of universal varicella vaccination on 1-year olds in Uruguay: 1997-2005. Archives of Disease in Childhood 2008;93:845-50.
291. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 5.2. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2012.
292. Sadzot-Delvaux C, Rentier B, Wutzler P, Asano Y, Suga S, Yoshikawa T, et al.Varicella vaccination in Japan, South Korea, and Europe. Journal of Infectious Diseases 2008;197(Suppl 2):185-90.
293. Sharrar RG, LaRussa P, Galea SA, Steinberg SP, Sweet AR, Keatley RM, et al.The postmarketing safety profile of varicella vaccine. Vaccine 2000;19(7-8):916-23.
294. Simpson REH. Infectiousness of communicable diseases in the household (measles, chickenpox, and mumps). Lancet 1952;ii:549-54.
295. Skull SA, Wang EE. Varicella vaccination - a critical review of the evidence. Archives of Disease in Childhood 2001;85(2):83-90.
296. Takahashi M. The varicella vaccine. Vaccine development. Infectious Disease Clinics of North America 1996;10(3):469-88.